Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10160182 | 0.83 | LMNA (0.35) | CYP4F2CYP4A11CHRM1CYP2D6CYP2C19 | |
| SCHEMBL24960420 | 0.81 | SCN1A (0.31) | CHRM1CYP2D6CYP2C19 | |
| SCHEMBL23624135 | 0.81 | CYP4F2 (0.34) | CYP4F2CYP4A11CHRM1LMNANPSR1 | |
| SCHEMBL30834944 | 0.81 | CYP4F2 (0.41) | CYP4F2CYP4A11CHRM1LMNANPSR1 | |
| SCHEMBL25135435 | 0.81 | CYP2D6 (0.33) | CYP2D6CYP2C19FFAR4 | |
| SCHEMBL25415119 | 0.79 | CYP4F2 (0.33) | CYP4F2CYP4A11CHRM1LMNANPSR1 | |
| SCHEMBL23639717 | 0.79 | CHRM1 (0.35) | CYP4F2CYP4A11CHRM1LMNANPSR1 | |
| SCHEMBL24960887 | 0.78 | CYP2D6 (0.32) | CYP2D6CYP2C19 | |
| SCHEMBL16055077 | 0.77 | CYP4F2 (0.36) | CYP4F2CYP4A11CHRM1LMNANPSR1 | |
| SCHEMBL13593976 | 0.77 | PKM (0.35) | CYP4F2CYP4A11CHRM1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230105212-A1 | BIPHENYL DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105212-A1 | BIPHENYL DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, TMBIM6, CYP46A1 | CYP4F2 21/4885CYP4A11 18/4885CHRM1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.